CN118146148A - 吡啶氮氧化合物及其制备方法和用途 - Google Patents
吡啶氮氧化合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN118146148A CN118146148A CN202410255352.5A CN202410255352A CN118146148A CN 118146148 A CN118146148 A CN 118146148A CN 202410255352 A CN202410255352 A CN 202410255352A CN 118146148 A CN118146148 A CN 118146148A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- cycloalkyl
- membered heterocycloalkyl
- pain
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910863718 | 2019-09-12 | ||
| CN2019108637186 | 2019-09-12 | ||
| CN2019110947829 | 2019-11-11 | ||
| CN201911094782 | 2019-11-11 | ||
| CN2020105313811 | 2020-06-11 | ||
| CN202010531381 | 2020-06-11 | ||
| CN202010923311 | 2020-09-04 | ||
| CN2020109233110 | 2020-09-04 | ||
| PCT/CN2020/114700 WO2021047622A1 (zh) | 2019-09-12 | 2020-09-11 | 吡啶氮氧化合物及其制备方法和用途 |
| CN202080037787.2A CN113906013B (zh) | 2019-09-12 | 2020-09-11 | 吡啶氮氧化合物及其制备方法和用途 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080037787.2A Division CN113906013B (zh) | 2019-09-12 | 2020-09-11 | 吡啶氮氧化合物及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118146148A true CN118146148A (zh) | 2024-06-07 |
Family
ID=74866555
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410255352.5A Pending CN118146148A (zh) | 2019-09-12 | 2020-09-11 | 吡啶氮氧化合物及其制备方法和用途 |
| CN202080037787.2A Active CN113906013B (zh) | 2019-09-12 | 2020-09-11 | 吡啶氮氧化合物及其制备方法和用途 |
| CN202010957957.0A Active CN112479996B (zh) | 2019-09-12 | 2020-09-11 | 吡啶氮氧化合物及其制备方法和用途 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080037787.2A Active CN113906013B (zh) | 2019-09-12 | 2020-09-11 | 吡啶氮氧化合物及其制备方法和用途 |
| CN202010957957.0A Active CN112479996B (zh) | 2019-09-12 | 2020-09-11 | 吡啶氮氧化合物及其制备方法和用途 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230303495A9 (https=) |
| EP (1) | EP4043437A4 (https=) |
| JP (1) | JP2022548104A (https=) |
| KR (1) | KR20220101606A (https=) |
| CN (3) | CN118146148A (https=) |
| AU (1) | AU2020346951A1 (https=) |
| BR (1) | BR112022004495A8 (https=) |
| CA (1) | CA3150400A1 (https=) |
| CL (1) | CL2022000619A1 (https=) |
| CO (1) | CO2022004594A2 (https=) |
| GE (2) | GEP20247688B (https=) |
| MX (1) | MX2022003032A (https=) |
| PE (1) | PE20221515A1 (https=) |
| PH (1) | PH12022550584A1 (https=) |
| TW (1) | TWI770607B (https=) |
| WO (1) | WO2021047622A1 (https=) |
| ZA (1) | ZA202204100B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116829539B (zh) * | 2021-03-11 | 2025-11-25 | 上海济煜医药科技股份有限公司 | 吡啶氮氧化合物晶型及其应用 |
| HRP20260068T1 (hr) | 2021-06-04 | 2026-02-27 | Vertex Pharmaceuticals Incorporated | Čvrsti farmaceutski oblici i režimi doziranja koji obuhvaćaju (2r,3s,4s,5r)-4-[[3-(3,4-difluor-2-metoksifenil)-4,5-dimetil-5-(trifluormetil)tetrahidrofuran-2-karbonil]amino]piridin-2-karboksamid |
| CA3221938A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| AU2022283934A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| SMT202500481T1 (it) | 2021-06-04 | 2026-01-12 | Vertex Pharma | N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio |
| US20240400544A1 (en) | 2021-06-04 | 2024-12-05 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| WO2022256842A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| MX2024008057A (es) | 2021-12-30 | 2024-08-28 | Biomea Fusion Inc | Compuestos de pirazina como inhibidores de flt3. |
| CN116891432A (zh) * | 2022-04-02 | 2023-10-17 | 武汉人福创新药物研发中心有限公司 | Nav1.8抑制剂及其用途 |
| US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CA3257285A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| WO2023205463A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CA3256248A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| WO2023232117A1 (zh) | 2022-06-02 | 2023-12-07 | 上海济煜医药科技有限公司 | 吡啶氮氧化合物的制备方法 |
| AU2023287273A1 (en) * | 2022-06-22 | 2025-01-09 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Nav1.8 inhibitor |
| WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| WO2024153856A1 (en) * | 2023-01-18 | 2024-07-25 | Orion Corporation | Process for the preparation of 3-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamido)pyridine 1-oxide |
| CN121419965A (zh) * | 2023-06-14 | 2026-01-27 | 上海济煜医药科技股份有限公司 | 吡啶氮氧化合物的盐型、共晶及其制备方法和应用 |
| TW202500551A (zh) * | 2023-06-14 | 2025-01-01 | 大陸商上海濟煜醫藥科技有限公司 | 吡啶氮氧化合物與富馬酸的共晶體及其組合物、用途和製備方法 |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| WO2025124502A1 (zh) * | 2023-12-13 | 2025-06-19 | 武汉人福创新药物研发中心有限公司 | 一种Nav1.8抑制剂化合物及其盐、多晶型和用途 |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (en) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834468A (en) * | 1995-07-07 | 1998-11-10 | Zeneca Limited | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists |
| MX295245B (es) * | 2005-06-21 | 2012-01-26 | Mitsui Chemicals Inc | Derivado de amida e insecticida que contiene el mismo. |
| EP2004596A2 (en) * | 2006-04-11 | 2008-12-24 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
| JP2010047480A (ja) * | 2006-12-19 | 2010-03-04 | Mitsui Chemicals Inc | 虫害の予防方法 |
| KR20100075631A (ko) * | 2007-10-11 | 2010-07-02 | 버텍스 파마슈티칼스 인코포레이티드 | 전압개폐 나트륨 채널의 억제제로서 유용한 아릴 아미드 |
| WO2009049181A1 (en) * | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Amides useful as inhibitors of voltage-gated sodium channels |
| EP2655330B1 (en) * | 2010-12-22 | 2016-02-10 | Purdue Pharma LP | Substituted pyridines as sodium channel blockers |
| RU2683788C2 (ru) * | 2013-01-31 | 2019-04-02 | Вертекс Фармасьютикалз Инкорпорейтед | Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов |
| CA2898653C (en) * | 2013-01-31 | 2021-09-28 | Vertex Pharmaceuticals Incorporated | Amides as modulators of sodium channels |
| RS56015B1 (sr) * | 2013-01-31 | 2017-09-29 | Vertex Pharma | Piridon amidi kao modulatori natrijumovih kanala |
| CA2931550C (en) * | 2013-12-13 | 2023-09-26 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
| AU2018300150A1 (en) * | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| CA3105657A1 (en) * | 2018-07-09 | 2020-01-16 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting nav1.8 |
-
2020
- 2020-09-11 BR BR112022004495A patent/BR112022004495A8/pt unknown
- 2020-09-11 AU AU2020346951A patent/AU2020346951A1/en not_active Abandoned
- 2020-09-11 GE GEAP202015928A patent/GEP20247688B/en unknown
- 2020-09-11 CN CN202410255352.5A patent/CN118146148A/zh active Pending
- 2020-09-11 PE PE2022000407A patent/PE20221515A1/es unknown
- 2020-09-11 TW TW109131318A patent/TWI770607B/zh active
- 2020-09-11 CN CN202080037787.2A patent/CN113906013B/zh active Active
- 2020-09-11 WO PCT/CN2020/114700 patent/WO2021047622A1/zh not_active Ceased
- 2020-09-11 PH PH1/2022/550584A patent/PH12022550584A1/en unknown
- 2020-09-11 US US17/642,020 patent/US20230303495A9/en not_active Abandoned
- 2020-09-11 JP JP2022516434A patent/JP2022548104A/ja active Pending
- 2020-09-11 GE GEAP202415928A patent/GEAP202415928A/en unknown
- 2020-09-11 CA CA3150400A patent/CA3150400A1/en active Pending
- 2020-09-11 EP EP20863934.4A patent/EP4043437A4/en active Pending
- 2020-09-11 CN CN202010957957.0A patent/CN112479996B/zh active Active
- 2020-09-11 MX MX2022003032A patent/MX2022003032A/es unknown
- 2020-09-11 KR KR1020227012157A patent/KR20220101606A/ko not_active Ceased
-
2022
- 2022-03-11 CL CL2022000619A patent/CL2022000619A1/es unknown
- 2022-04-11 ZA ZA2022/04100A patent/ZA202204100B/en unknown
- 2022-04-11 CO CONC2022/0004594A patent/CO2022004594A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4043437A1 (en) | 2022-08-17 |
| BR112022004495A2 (pt) | 2022-05-31 |
| US20230026907A1 (en) | 2023-01-26 |
| PE20221515A1 (es) | 2022-10-04 |
| CN113906013B (zh) | 2024-03-12 |
| GEP20247688B (en) | 2024-11-11 |
| MX2022003032A (es) | 2022-07-12 |
| EP4043437A4 (en) | 2023-10-04 |
| CN112479996B (zh) | 2023-05-26 |
| BR112022004495A8 (pt) | 2023-04-18 |
| AU2020346951A1 (en) | 2022-04-28 |
| CN112479996A (zh) | 2021-03-12 |
| CN113906013A (zh) | 2022-01-07 |
| KR20220101606A (ko) | 2022-07-19 |
| TWI770607B (zh) | 2022-07-11 |
| WO2021047622A1 (zh) | 2021-03-18 |
| JP2022548104A (ja) | 2022-11-16 |
| PH12022550584A1 (en) | 2024-03-04 |
| GEAP202415928A (en) | 2024-07-10 |
| CL2022000619A1 (es) | 2022-10-28 |
| CO2022004594A2 (es) | 2022-07-08 |
| US20230303495A9 (en) | 2023-09-28 |
| ZA202204100B (en) | 2024-04-24 |
| CA3150400A1 (en) | 2021-03-18 |
| TW202114990A (zh) | 2021-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113906013B (zh) | 吡啶氮氧化合物及其制备方法和用途 | |
| CN112225695B (zh) | 一种氮氧化合物及其制备方法和用途 | |
| JP2022548104A5 (https=) | ||
| US12246008B2 (en) | 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels | |
| CN112457294A (zh) | 一种作为NaV1.8阻滞剂的化合物及其制备方法和用途 | |
| US11292799B2 (en) | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | |
| US20210188808A1 (en) | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | |
| WO2022235859A1 (en) | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors | |
| EP3828174A1 (en) | Pyridazinone derivative | |
| US20240400547A1 (en) | 2,6-piperidinedione compound and application thereof | |
| BR112019014688A2 (pt) | Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-il como inibidores de magl | |
| KR20240019064A (ko) | 피리딘 질소 산화물 화합물의 결정 형태 및 이의 용도 | |
| JP2022526295A (ja) | キノリンおよびキナゾリン化合物およびその使用方法 | |
| US11299497B2 (en) | Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | |
| CN117510463A (zh) | Kif18a抑制剂化合物、药物组合物及其制备方法和应用 | |
| EP3283487B1 (en) | Pyridopyrimidinones and their use as nmda receptor modulators | |
| JP7812861B2 (ja) | サイクリン依存性キナーゼ７（ｃｄｋ７）阻害剤としての三環式ピリミジン | |
| KR20220106778A (ko) | 간 x 수용체 작용제로서의 1,2,4-옥사디아졸 유도체 | |
| EP2546255A1 (en) | Benzazepine compound | |
| HK40061625A (en) | Pyridine oxynitride, preparation method therefor and use thereof | |
| HK40061625B (zh) | 吡啶氮氧化合物及其制备方法和用途 | |
| WO2019037791A1 (zh) | 一种长效雷沙吉兰前药及其制备方法和用途 | |
| KR20190040340A (ko) | 장애의 치료를 위한 하이드록시노르케타민 유도체 | |
| US20250255848A1 (en) | Substituted 6,7-dihydro-5h-benzo[7]annulene derivatives, processes for their preparation and therapeutic uses thereof | |
| EP4617267A1 (en) | Thioether compound having soft drug property and use thereof, and pharmaceutical composition and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20250402 Address after: 201315, 1st Floor, No. 2, Lane 535, Huanqiao Road, Pudong New Area, Shanghai Applicant after: Shanghai Jiyu Pharmaceutical Technology Co.,Ltd. Country or region after: China Address before: 201203 1st floor, building 1, No. 1118, Halley Road, Pudong New Area pilot Free Trade Zone, Shanghai Applicant before: Shanghai Jiyu Pharmaceutical Technology Co.,Ltd. Country or region before: China Applicant before: JIANGXI JEMINCARE GROUP Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Country or region after: China Address after: 201315, 1st Floor, No. 2, Lane 535, Huanqiao Road, Pudong New Area, Shanghai Applicant after: Shanghai Jiyu Pharmaceutical Technology Co., Ltd. Address before: 1st Floor, No. 2, Lane 535, Huanqiao Road, Pudong New Area, Shanghai Applicant before: Shanghai Jiyu Pharmaceutical Technology Co.,Ltd. Country or region before: China |